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Abstract
Background: Widespread abdominal imaging has led to a substantial increase in the detection of incidentalomas. Currently,
an increasing number of centers offer surveillance of the pancreas to individuals at high risk (IARs) of pancreatic ductal
adenocarcinoma (PDAC).
Objective: The aims of this study were to evaluate the frequency and type of incidental findings in a magnetic resonance
imaging (MRI)-based surveillance program for IARs for PDAC, and to discuss the benefit of detecting these lesions.
Methods: The outcome of MRI screening was reviewed in 568 individuals from three long-term pancreas surveillance
programs conducted at three large European expert centers. All MRIs were studied in detail for the presence of incidental
lesions.
Results: The most common lesions were liver cysts, renal cysts and liver hemangioma, which together comprised 75% of all
lesions. Only five (0.9%) patients underwent surgery for a benign lesion. Cancer was detected in 11 patients (1.9%); early
detection of tumors was beneficial in at least five cases.
Conclusion: The present study demonstrates that extrapancreatic incidentaloma is a common finding in IARs for PDAC, but
rarely requires additional treatment. CDKN2A-p16-Leiden mutation carriers were the only patient group found to harbor a
substantial number of cancers, and detection resulted in benefit in several cases.
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Introduction
The widespread use of magnetic resonance imaging
(MRI) and computed tomography (CT) has led to a
substantial increase in the detection of incidental find-
ings, more commonly referred to as incidentalomas.
The most frequent and extensively described incidenta-
lomas found with abdominal imaging are adrenal
masses, liver cysts and renal cysts. The clinical
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significance of these lesions is often unknown. The
management of an incidentaloma depends on the site,
size and type of the lesion. Several guidelines have been
published with detailed recommendations for manage-
ment of these lesions.1–5 Experience has shown that
with additional imaging and subsequent surgical inter-
vention, most lesions prove to be benign. Currently, an
increasing number of centers offer surveillance of the
pancreas to individuals at high risk (IARs) of pancre-
atic ductal adenocarcinoma (PDAC), usually involving
MRI and/or endoscopic ultrasonography (EUS).6–9
These IARs can be subdivided into two groups: (1)
patients with an underlying gene defect associated
with a high risk of PDAC, most commonly BRCA2
or CDKN2A mutations, and (2) patients with a positive
family history of PDAC, also known as familial
pancreatic cancer (FPC). Detection of extrapancreatic
incidental lesions in these high-risk groups may offer
benefit if the lesion is (pre)malignant. However, if
only benign lesions are found, additional imaging and
surgical intervention might be a burden, especially in
high-risk groups that already undergo surveillance for
multiple cancers.
In the present study, we evaluated the frequency of
extrapancreatic incidentalomas in large, long-term,
prospective surveillance programs for PDAC at
three European expert centers. The aims of this study
were (1) to evaluate the occurrence and type of
extrapancreatic incidental findings in these surveillance
programs, and (2) to assess the benefit of detecting
these lesions.
Methods
The current study was made possible through the col-
laboration of three tertiary referral centers: the
Department of Surgery at Philipps University in
Marburg, Germany, the Department of Medical
Oncology at Ramon y Cajal University Hospital in
Madrid, Spain, and the Department of
Gastroenterology & Hepatology at Leiden University
Medical Center in Leiden, The Netherlands. The study
design was a retrospective evaluation of an ongoing
prospective follow-up study.7,8,10 In Leiden, a surveil-
lance program was initiated for carriers of a CDKN2A-
p16-Leiden mutation in the year 2000. In Marburg a
similar program was introduced, mainly for families
with FPC, in 2002. In 2010 a surveillance program
was initiated in Madrid for various high-risk groups.
The surveillance tools included MRI and EUS of the
pancreas. The total number of individuals, the charac-
teristics of the various high-risk groups and the surveil-
lance methods implemented at each center are
summarized in Table 1.
All MRIs were studied in detail for the presence of
incidental findings including cysts, solid lesions, focal
nodular hyperplasia (FNH), hemangioma and cancers.
For all patients with an incidental lesion, further infor-
mation was collected on whether additional imaging,
intervention or surgery was performed. The observa-
tion time was from the start of a screening program
up to 1 January 2018. The study was approved by the
ethics committees of the respective centers.
Table 1. Characteristics of participants (n¼ 568) in pancreas surveillance programs in three European expert centers.
Leiden Madrid Marburg
Year started surveillance 2000 2010 2002
FPC – 52 240
FDR with PC< 50 – 5 –
HBOC – 19 –
BRCA1 or 2 mutation carrier – 1 14
Lynch syndrome – 1 –
Familial adenomatous polyposis – - 1
STK11-mutation – – 2
CDKN2A-p16-Leiden mutation 217 2 4
PALB2-mutation – – 7
FPC/Lynch Syndrome/HBOC – 1 –
FPC/HBOC – 2 –
Surveillance protocol MRI with optional
EUS since 2012
Annual MRI and EUS Annual MRI and EUS
every three years
Total number of IARs 217 83 268
EUS: endoscopic ultrasound; FDR: first-degree relative; FPC: familial pancreatic cancer; HBOC: hereditary breast ovarian cancer; IARs: individuals at high
risk; MRI: magnetic resonance imaging; PC: pancreatic cancer.
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Oral or written informed consent was received from
all patients. The study protocol conforms to the ethical
guidelines of the 1975 Declaration of Helsinki.
Results
Leiden, the Netherlands
Of the 217 IARs under surveillance in Leiden during
the study period, 214 were carriers of a CDKN2A-p16-
Leiden mutation while three had a pathogenic variant
in CDKN2A. Ninety-four were male (43.3%) and 123
(56.7%) female. The mean age at start of surveillance
was 51.5 years (range, 36.2–72.2 years), with a median
follow-up time of 4.7 years (range, 0.0–16.9 years). A
total of 117 extrapancreatic findings were observed,
most frequently in the liver, including cysts (29%),
adenoma/FNH (9%) and hemangioma (21%)
(Table 2). One patient underwent an additional ultra-
sonography and a fine-needle aspiration–biopsy
because of a suspected lesion in the liver that proved
to be an FNH.
Incidentalomas in the adrenal glands (adrenaloma)
were identified in 12 cases (10.3%). In two of the 12
cases the lesion was removed during pancreatic surgery
for a solid lesion. The first patient was a 40-year-old
homozygote p16-Leiden carrier with a solid lesion in the
uncinate process of the pancreas, together with a mass
in the right adrenal gland detected on the first MRI. CT
confirmed both lesions and defined the adrenal mass as
an adrenaloma of 3.5 cm. A pancreaticoduodenectomy
was performed and the adrenal mass was resected.
Pathological examination revealed a PDAC and an
adrenal adenoma without evidence of malignancy.
The second patient was a 66-year-old woman who
came for her first MRI scan. The MRI showed a mass
in the adrenal gland of 2.4 cm, together with a 1 cm
hypovascular mass in the uncinate process. Subsequent
CT confirmed both lesions but could not define the adre-
nal mass. The patient underwent a pancreaticoduode-
nectomy and an adrenalectomy. Pathological
examination showed an intraductal papillary mucinous
neoplasm with low-grade dysplasia, and an adrenaloma
of 2.4 cm with adrenocortical hyperplasia.
Other frequently detected lesions are shown in
Table 2. In seven cases (3.2%) various cancers were
found outside the pancreas including two renal cell car-
cinomas, one colorectal cancer (CRC), a neuroendo-
crine carcinoma in the liver, a stromal tumor in the
stomach and metastases of breast cancer and melan-
oma. Details of these findings are summarized in
Table 3. In four of these patients the early detection
of cancer was beneficial.
Madrid, Spain
Eighty-three IARs were under surveillance, consisting
of 37 men (44.6%) and 46 women (55.4%). The ana-
lyzed cohort included a number of high-risk groups.
Forty-two belonged to FPC families, five individuals
had a first-degree relative with PDAC younger than
50 years, 19 belonged to a hereditary breast ovarian
cancer (HBOC) family, one individual was a BRCA2
carrier, one belonged to a Lynch syndrome family, two
had a CDKN2A-p16-Leiden mutation, one belonged to
a family with evidence of combined FPC, Lynch syn-
drome and HBOC, and two belonged to a family with
mixed FPC/HBOC. The mean age at start of surveil-
lance was 50 years (range, 29–81 years), with a median
follow-up time of 2.9 years (range, 0.1–6.7 years).
In total, 122 incidental lesions were detected in 83 indi-
viduals (Table 2). Liver cysts (29.5%) were the most
commonly found lesions and renal cysts were the
second most common finding (19.7%).
In none of the patients was surgical management
required. There was one patient who required add-
itional imaging after a solid renal tumor was found
(0.8%), but the lesion was characterized as an
angiolipoma.
Marburg, Germany
Of the 268 IARs under surveillance in Marburg during
the study, 109 were men (40.7%) and 159 were women
(59.3%). Average age at start of screening was 48 years
(range, 25–75 years) and the median follow-up time was
three years (range, 0.1–14.6 years). The cohort included
240 individuals with FPC, four BRCA1 mutation car-
riers, 10 BRCA2 carriers, seven PALB2 mutation car-
riers, four CDKN2A/p16-Leiden mutation carriers, two
STK11 mutation carriers and one patient with familial
Table 2. Total number of incidental extrapancreatic lesions in the
three European cohorts.
Lesions Leiden Madrid Marburg Total (%)
Hemangioma liver 25 5 25 55 (12.0%)
Adenoma/FNH liver 10 - 3 13 (2.8%)
Cyst liver 34 36 100 170 (37.0%)
Cyst kidney 17 24 75 116 (25.3%)
Cyst breast 2 - 1 3 (0.7%)
Adrenal lesion 12 2 12 26 (5.7%)
Aortic aneurysm 3 - - 3 (0.7%)
Cancer 7 - 4 11 (2.4%)
Other lesions 7 55 - 62 (13.5%)
Total number of
lesions
117 122 220 459 (100%)
FNH: focal nodular hyperplasia.
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adenomatous polyposis with PDAC. A total of 220
lesions were identified in the 268 patients (Table 2).
The most common findings were cysts in the liver
(45.5%) or kidney (34.1%). Adrenaloma were observed
in 12 cases (5.4%). Liver cysts in two patients and a
renal cyst in one patient (1.1% of all patients) required
surgical removal.
Regarding the need for additional investigations, the
two patients who had surgery for liver lesions had an
additional contrast-enhanced ultrasonography.
Another 47-year-old man had an additional gastros-
copy because EUS gave a suspicion of a MALT
(mucosa-associated lymphoma tissue) lymphoma,
which was a peptic ulcer. In a 43-year-old woman, a
mammography was performed because MRI showed
contrast-enhancing lesions in both breasts.
Mammography diagnosed fibroadenomas. In another
51-year-old female patient, a 53 50mm solid liver
lesion on MRI was further evaluated by contrast-
enhanced ultrasonography, which confirmed a
hemangioma.
Cancer was identified in four (1.5%) patients
(Table 4). The first patient was a 55-year-old woman
who underwent surgery for breast cancer in 2004.
Undergoing screening for pancreatic cancer 12 years
later, MRI revealed multiple lesions in the right ilium
and lumbar spine that proved to be bone metastases of
breast cancer.
The second patient was a 60-year-old woman
undergoing MRI surveillance in 2011. The MRI
showed a lesion in the liver, with cholestasis and peri-
portal edema. This lesion turned out to be a bile duct
carcinoma (Bismuth stage IIIa). The patient underwent
extended liver resection but unfortunately died two
weeks later of postoperative liver failure.
The third patient was a 48-year-old female patient
who underwent surgery because of breast cancer in
2014. A year later the patient underwent pancreatic
cancer screening. MRI showed multiple lesions of the
thoracic and lumbar spine, which proved to be bone
metastases of the breast cancer. One year later, liver
metastases were detected. The patient is still alive.
The detection of the cancers (or metastatic cancers)
by the PDAC screening program did not result in a cure
for any of these three patients.
The fourth patient, a 52-year-old man, showed a
15mm, partially cystic cortical lesion of the left
kidney with thick walls. This lesion was resected and
turned out to be a renal cell carcinoma. The patient is
alive without evidence of disease at last follow-up.
Discussion
The present study shows that MRI-based pancreas sur-
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a large number of incidental lesions. The most com-
monly found lesions were liver cysts, renal cysts and
liver hemangioma, which together accounted for 74%
of all incidental lesions, followed by adrenal incidenta-
loma in 6% of patients. Only five (0.9%) patients
underwent surgery for a benign lesion: two patients
for a liver cyst, one for a renal cyst and two for an
adrenal incidentaloma.
Cancer was detected in 11 patients (1.9%), including
seven CDKN2A-p16-Leiden mutation carriers, and
metastatic disease was detected in six of the 11 patients.
Early detection of tumors was beneficial in at least five
of the patients.
Several studies have reported frequencies of inciden-
tal findings detected during abdominal imaging. One
study reported the rate of incidental findings of whole-
body MRI in 148 healthy control participants.11 The
most frequently found abnormalities were renal cysts
(42.9%), gallstones (12.2%) and liver cysts/hemangioma
(10.2%). In a similar study whole-body MRI was per-
formed in 118 healthy individuals.12 A total of 106 inci-
dental lesions were found in the 83 individuals with an
abnormality, the most common lesions being renal cysts
(16.0%), liver hemangioma (12.3%) and liver cysts
(11.3%). These findings are in agreement with our find-
ings for benign lesions. However, the rate of incidentally
detected cancers in the subgroup of CDKN2A-p16-
Leiden mutation carriers was much higher.
What was the benefit of the detection of incidental
lesions in our study? Although incidental findings were
frequent, only 0.9% of the total group of IARs under-
went a surgical intervention for a lesion, which was then
found to be benign in all cases. A primary cancer, metas-
tases of a previous cancer or a new cancer was detected in
1.9%. By contrast, in the Leiden cohort of CDKN2A-
p16-Leiden mutation carriers, extrapancreatic cancer
was detected in a substantial proportion of patients
(seven patients out of 217 (3.2%)). The early detection
of cancers in seven mutation carriers allowed curative
resection of renal cancers in two patients, a gastric stro-
mal tumor in one patient and colonic resection (and early
start of chemotherapy) in one patient with CRC. In the
German cohort, the detection of a renal cell carcinoma
allowed curative resection. In addition, the identification
of metastatic breast cancer in two patients allowed the
early start of chemotherapy.
Strengths of the current study include the substantial
size of the study group, the wide variation of high-risk
groups and the long follow-up time. A possible limita-
tion was that we are not informed about which defin-
itions were used for a significant incidentaloma in the
three expert centers and which guidelines for their
management.
What are the clinical implications of our findings?
First, it is important to inform all participants at the
start of the surveillance program about the possibility
of detecting incidental lesions. Based on our findings, it
might be explained to patients that lesions are almost
always harmless and will not require additional treat-
ment. However, carriers of a CDKN2A-p16-Leiden
mutation should be told that cancer might be detected
outside the pancreas in a small proportion of patients.
To improve the investigation of the pancreas, there
is currently a trend toward restricting MRI scanning to
the pancreas only. However, to avoid missing cancers
located outside the pancreas in CDKN2A-p16-Leiden
mutation carriers, MRI assessment should include at
least one scan of all abdominal organs.
In summary, the present study demonstrates that
incidentaloma is a common finding in IARs for
PDAC, but rarely requires additional treatment.
CDKN2A-p16-Leiden mutation carriers were the only
patient group found to harbor a substantial number of
cancers, and detection resulted in benefit in several
cases.
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